Opendata, web and dolomites

MYA

MYA, the innovative diagnostics platform for the full mapping of personal allergies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYA project word cloud

Explore the words cloud of the MYA project. It provides you a very rough idea of what is the project "MYA" about.

specialists    pharmacies    turn    price    agree    efficiency    150    units       inadequate    treatment    public    extreme    chronic    conveniently    primary    affordable    care    array    500    population    patients    full    personal    ready    quality    international    either    limited    advice    inhalant    prescribe    quantitatively    revenues    incurred    launch    mya    map    saved    treatments    relieve    suffering    risk    screening    contact    detect    serve    website    made    ship    benefits    worldwide    cumulative    laboratories    disease    saturated    allergen    time    weeks    individuals    patient    costly    gets    immunoglobulin    caused    million    accessible    self    network    provision    allergies    reducing    proper    entails    report    personalized    allergens    days    immune    run    centres    created    food    alltox    ige    collect    healthcare    selling    detection    diagnosis    life    allergy    plex    profile    scarcity    420    society    diagnostic    market   

Project "MYA" data sheet

The following table provides information about the project.

Coordinator
ALLTOX S.R.L. 

Organization address
address: VIA SARDEGNA 38
city: MILANO
postcode: 20146
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.alltox.it/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALLTOX S.R.L. IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Allergies are chronic conditions caused by an extreme immune response to inhalant and food allergens that affect today 500 million (M) individuals worldwide and 150 M in Europe. International institutions all agree in the benefits that early allergy diagnosis and targeted treatment could bring to society. However, only 5% of the population gets a proper diagnosis, either due to limited awareness or scarcity of allergy specialists. Thus, patients try to self-manage their condition and non-specialists prescribe inadequate treatments. Therefore, the patient’s quality of life could be improved if allergy diagnosis were made accessible to the general public. Also, € 30 M/year would be saved in Europe by enhancing the efficiency of our healthcare system. In response, ALLTOX has created MYA (Map Your Allergies), a high quality, cost-effective test for allergy screening. Our 40-plex array-based technology will serve to quantitatively detect the patient’s immunoglobulin IgE, which are produced by the immune system upon contact with a particular allergen. The personal allergy profile can be obtained and thus, facilitate an adequate management. MYA will be offered to the general public at an affordable price through a network of pharmacies and primary care centres, who will collect the sample and ship it to our selected laboratories to run the analysis. In only 3 days, a full report and personalized advice will be conveniently available to the patient through our website, greatly reducing the current time-to-diagnosis (8 weeks). Our product entails a cost-effective diagnostic test that will facilitate detection of allergy risk and provision of adequate management to those patients suffering from this chronic disease. Also, the MYA test will help to relieve the costly impact incurred by allergies on our ready saturated healthcare system. In turn, MYA will provide ALLTOX estimated cumulative revenues of €40.2 M after selling 420 000 units within five years from market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More